<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05067972</url>
  </required_header>
  <id_info>
    <org_study_id>C4431001</org_study_id>
    <nct_id>NCT05067972</nct_id>
  </id_info>
  <brief_title>A Study of PF-07260437 in Advanced or Metastatic Solid Tumors</brief_title>
  <acronym>C4431001</acronym>
  <official_title>A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTITUMOR ACTIVITY OF PF-07260437 IN ADVANCED OR METASTATIC SOLID TUMORS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD),&#xD;
      and antitumor activity of PF-07260437, a B7-H4 x CD3 bispecific mAb, in participants aged ≥18&#xD;
      years of age with advanced or metastatic breast cancer, ovarian cancer or endometrial cancer.&#xD;
      Adult participants with other advanced or metastatic high B7-H4 expressing tumors may be&#xD;
      considered after discussion with and approval from sponsor.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 7, 2021</start_date>
  <completion_date type="Anticipated">February 22, 2025</completion_date>
  <primary_completion_date type="Anticipated">February 22, 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with dose limiting toxicities (DLTs) in Dose escalation</measure>
    <time_frame>Baseline through 28 days after first dose</time_frame>
    <description>DLTs will be evaluated in Part 1. The number of DLTs will be used to determine the dose escalation decision and recommended dose of PF-07260437</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Baseline through up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant laboratory abnormalities</measure>
    <time_frame>Baseline through 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinical adverse events at the recommended dose for expansion</measure>
    <time_frame>Baseline through up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant laboratory abnormalities at recommended dose for expansion</measure>
    <time_frame>Baseline through 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with immune related adverse events</measure>
    <time_frame>Baseline through 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single dose: Maximal concentration (Cmax)</measure>
    <time_frame>Cycle 1 (each cycle is 28 days), Cycle 2, Cycle 3, and Day 1 of each subsequent cycle through end of treatment, up to about 2 years</time_frame>
    <description>PK assessment for PF-07260437</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximal plasma concentration (Tmax)</measure>
    <time_frame>Cycle 1 (each cycle is 28 days), Cycle 2, Cycle 3, and Day 1 of each subsequent cycle through end of treatment, up to about 2 years</time_frame>
    <description>PK assessment of PF-07260437</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single dose: Area Under the Curve (AUClast)</measure>
    <time_frame>Cycle 1 (each cycle is 28 days), Cycle 2, Cycle 3, and Day 1 of each subsequent cycle through end of treatment, up to about 2 years</time_frame>
    <description>PK assessment of PF-07260437</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-live (t1/2)</measure>
    <time_frame>Cycle 1 (each cycle is 28 days), Cycle 2, Cycle 3, and Day 1 of each subsequent cycle through end of treatment, up to about 2 years</time_frame>
    <description>PK assessment of PF-07260437</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve from Time Zero to Extrapolated Infinite Time (AUCinf)</measure>
    <time_frame>Cycle 1 (each cycle is 28 days), Cycle 2, Cycle 3, and Day 1 of each subsequent cycle through end of treatment, up to about 2 years</time_frame>
    <description>PK assessment of PF-07260437</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F)</measure>
    <time_frame>Cycle 1 (each cycle is 28 days) Cycle 2, Cycle 3, and Day 1 of each subsequent cycle through end of treatment, up to about 2 years</time_frame>
    <description>PK assessment of PF-0260347</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio (Rac)</measure>
    <time_frame>Cycle 1 (each cycle is 28 days), Cycle 2, Cycle 3 and Day 1 of each subsequent cycle through end of treatment, up to about 2 years</time_frame>
    <description>PK assessment for PF-07260437</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Oral Clearance (CL/F)</measure>
    <time_frame>Cycle 1 (each cycle is 28 days), Cycle 2, Cycle 3, and Day 1 of each subsequent cycle through end of treatment, up to about 2 years</time_frame>
    <description>PF assessment of PF-07260437</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Oral Clearance of Study Drug (CLss/F)</measure>
    <time_frame>Cycle 1 (each cycle is 28 days), Cycle 2, Cycle 3, and Day of each subsequent cycle through end of treatment, up to about 2 years</time_frame>
    <description>PK assessment for PF-07260437</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve at steady state under a dosing interval (AUCss,τ)</measure>
    <time_frame>Cycle 1 (each cycle is 28 days), Cycle 2, Cycle 3, and Day 1 of each subsequent cycle through end of treatment, up to about 2 years</time_frame>
    <description>PK assessment of PF-07260437</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration at Steady State (Cmax,ss)</measure>
    <time_frame>Cycle 1 (each cycle is 28 days), Cycle 2, Cycle 3, and Day 1 of each subsequent cycle through end of treatment, up to about 2 years</time_frame>
    <description>PK assessment of PF-07260437</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum Observed Plasma Concentration at Steady State (Tmax,ss)</measure>
    <time_frame>Cycle 1 (each cycle is 28 days), Cycle 2, Cycle 3, and Day 1 of each subsequent Cycle through end of treatment, up to about 2 years</time_frame>
    <description>PK assessment of PF-07260437</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Observed Plasma Trough Concentration at Steady State (Cmin,ss)</measure>
    <time_frame>Cycle 1 (each cycle is 28 days), Cycle 2, Cycle 3 and Day 1 of each subsequent cycle through end of treatment, up to about 2 years.</time_frame>
    <description>PK assessment for PF-07260437</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incident and titers of anti-body drug antibody against PF-07260437</measure>
    <time_frame>Cycle 1 (each cycle is 28 days), Cycle 2, Cycle 3, and Day 1 of each subsequent cycle through end of treatment, up to about 2 years</time_frame>
    <description>Immunogenicity of PF-07260437</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incident and titers of anti-body neutralizing antibody against PF-07260437</measure>
    <time_frame>Cycle 1 (each cycle is 28 days), Cycle 2, Cycle 3, and Day 1 of each subsequent cycle through end of treatment, up to about 2 years</time_frame>
    <description>Immunogenicity of PF-07260437</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with immune related adverse events at the recommended dose for expansion</measure>
    <time_frame>Baseline through up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) in dose expansion</measure>
    <time_frame>Baseline through up to 2 years or until disease progression</time_frame>
    <description>DOR as assessed using RECIST 1.1 and irRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP) in dose expansion</measure>
    <time_frame>Baseline through up to 2 years or until disease progression</time_frame>
    <description>TTP as assessed using RECIST 1.1 and irRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) in dose expansion</measure>
    <time_frame>Baseline through up to 2 years or until disease progression</time_frame>
    <description>ORR as assessed using RECIST 1.1 and irRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Baseline through up to 2 years or until disease progression</time_frame>
    <description>PFS as assessed using RECIST 1.1 and irRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) in the Expansion Cohorts (Part 2)</measure>
    <time_frame>Baseline through up to 2 years</time_frame>
    <description>Proportion of participants alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phenotypes and quantity of tumor infiltrating lymphocytes (TIL) before and after PF-07260437 treatment</measure>
    <time_frame>28 days prior to first dose and 7 days within Cycle 2, Day 15 of PF-07260437</time_frame>
    <description>Immune Cells assessments from paired biopsies</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Ovarian Neoplasms</condition>
  <condition>Endometrial Neoplasms</condition>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Monotherapy dose escalation (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive PF-07260437</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion (Part 2A) - Tumor specific Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive PF-07260437</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion (Part 2B) - Tumor specific Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive PF-07260437</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion (Part 2C) - Tumor specific Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive PF07260437</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-07260437</intervention_name>
    <description>B7-H4 x CD3 bi-specific mAb</description>
    <arm_group_label>Dose Expansion (Part 2A) - Tumor specific Arm A</arm_group_label>
    <arm_group_label>Dose Expansion (Part 2B) - Tumor specific Arm B</arm_group_label>
    <arm_group_label>Dose Expansion (Part 2C) - Tumor specific Arm C</arm_group_label>
    <arm_group_label>Monotherapy dose escalation (Part 1)</arm_group_label>
    <other_name>B7-H4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>B7-H4 IHC</intervention_name>
    <description>B7-H4 expression</description>
    <arm_group_label>Dose Expansion (Part 2A) - Tumor specific Arm A</arm_group_label>
    <arm_group_label>Dose Expansion (Part 2B) - Tumor specific Arm B</arm_group_label>
    <arm_group_label>Dose Expansion (Part 2C) - Tumor specific Arm C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Part 1: Histological/cytological diagnosis of selected locally advanced or metastatic&#xD;
             breast cancer, endometrial cancer and ovarian cancer&#xD;
&#xD;
          -  Part 2A:In second line or more, participants with histological/cytological diagnosis&#xD;
             of locally advanced or metastatic HR+ HER2- breast cancer showing high B7-H4&#xD;
             expression&#xD;
&#xD;
          -  Part 2B: In second line or more participants with histological or cytological&#xD;
             diagnosis of locally advance or metastatic HR+ Her2- breast cancer or triple negative&#xD;
             breast cancer (TNBC) with no biomarker pre-selection&#xD;
&#xD;
          -  Part 2C: In second line or more participants with histological diagnosis of locally&#xD;
             advance or metastatic triple negative breast cancer with high B7-H4 expression&#xD;
&#xD;
          -  Thyroid function within normal laboratory range; in participants with abnormal thyroid&#xD;
             function if Free T4 is normal and participant is clinically euthyroid, participants is&#xD;
             eligible&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with any active malignancy within 3 years prior to enrollment&#xD;
&#xD;
          -  Participants with advanced/metastatic, symptomatic, visceral spread, that are at risk&#xD;
             of life-threatening complications in the short term (including participants with&#xD;
             massive uncontrolled effusions [pleural, pericardial, peritoneal], pulmonary&#xD;
             lymphangitis, and over 50% liver involvement).&#xD;
&#xD;
          -  History of Grade ≥3 immune mediated adverse events (including liver function tests&#xD;
             that where considered drug related and cytokine release syndrome) that was considered&#xD;
             related to prior immune modulatory therapy (eg, immune checkpoint inhibitors, co&#xD;
             stimulatory agents, etc.) and required immunosuppressive therapy within 1 year of&#xD;
             treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope (City of Hope National Medical Center, City of Hope Medical Center)</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C4431001</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 24, 2021</study_first_submitted>
  <study_first_submitted_qc>September 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2021</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer of Endometrium</keyword>
  <keyword>Cancer of the Endometrium</keyword>
  <keyword>Carcinoma of Endometrium</keyword>
  <keyword>Endometrial Cancer</keyword>
  <keyword>Endometrial Carcinoma</keyword>
  <keyword>Endometrium Cancer</keyword>
  <keyword>Neoplasms, Endometrial</keyword>
  <keyword>Cancer of Ovary</keyword>
  <keyword>Cancer of the Ovary</keyword>
  <keyword>Neoplasms, Ovarian</keyword>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Ovary Cancer</keyword>
  <keyword>Ovary Neoplasms</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Breast Carcinoma</keyword>
  <keyword>Breast Tumors</keyword>
  <keyword>Cancer of Breast</keyword>
  <keyword>Cancer of the Breast</keyword>
  <keyword>Human Mammary Carcinoma</keyword>
  <keyword>Malignant Neoplasm of Breast</keyword>
  <keyword>Malignant Tumor of Breast</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

